Table 1.
Summary of Clinical Characteristics and Adjuvant Examination Items in Patients with Osteosarcoma
| Characteristics | Training Cohort (n=45) | Validation cohort (n=45) | Total (n=90) | t or χ2 | P-value |
|---|---|---|---|---|---|
| Necrosis rate | |||||
| < 90% | 33 (73.3%) | 30 (66.7%) | 63 (70.0%) | 0.476 | 0.490 |
| ≥ 90% | 12 (26.7%) | 15 (33.3%) | 27 (30.0%) | ||
| Age (mean, years) | 18.31 | 17.67 | 17.99 | 0.263 | 0.793 |
| Gender | |||||
| Female | 15 (33.3%) | 16 (35.6%) | 31 (34.4%) | 0.000 | 1.000 |
| Male | 30 (66.7%) | 29 (64.4%) | 59 (65.6%) | ||
| Location | |||||
| Trunk | 7 (15.6%) | 10 (22.2%) | 17 (18.9%) | 1.509 | 0.680 |
| Humerus | 5 (11.1%) | 6 (13.3%) | 11 (12.2%) | ||
| Femur | 22 (48.9%) | 22 (48.9%) | 44 (48.9%) | ||
| Tibia and fibula | 11 (24.4%) | 7 (15.6%) | 18 (20.0%) | ||
| Tumor volume (mean, cm3) | 407 | 389 | 398 | 0.198 | 0.844 |
| MSTS staging | |||||
| II | 24 (53.3%) | 17 (37.8%) | 41 (45.6%) | 2.195 | 0.138 |
| III | 21 (46.7%) | 28 (62.2%) | 49 (54.4%) | ||
| CRP | |||||
| Normal | 29 (64.4%) | 30 (66.7%) | 59 (65.6%) | 0.049 | 0.824 |
| Elevated | 16 (35.6%) | 15 (33.3%) | 31 (34.4%) | ||
| ESR | |||||
| Normal | 14 (31.1%) | 17 (37.8%) | 31 (34.4%) | 0.443 | 0.506 |
| Elevated | 31 (68.9%) | 28 (62.2%) | 59 (65.6%) | ||
| LDH | |||||
| Normal | 36 (80.0%) | 25 (55.6%) | 61 (67.8%) | 6.156 | 0.013 |
| Elevated | 9 (20.0%) | 20 (44.4%) | 29 (32.2%) | ||
| ALP | |||||
| Normal | 35 (77.8%) | 29 (64.4%) | 64 (71.1%) | 1.947 | 0.163 |
| Elevated | 10 (22.2%) | 16 (35.6%) | 26 (28.9%) | ||
| Metastasis at the first visit | |||||
| Yes | 31 (68.9%) | 28 (62.2%) | 59 (65.6%) | 0.443 | 0.506 |
| No | 14 (31.1%) | 17 (37.8%) | 31 (34.4%) |
Note: Chi-square test and t-test were used to test the balance of sample distribution between training training cohort and validation cohort.
Abbreviations: ALP, alkaline phosphatase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase.